GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Vita 34 AG (XTER:V3V) » Definitions » Debt-to-EBITDA

Vita 34 AG (XTER:V3V) Debt-to-EBITDA : 2.70 (As of Sep. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Vita 34 AG Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Vita 34 AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was €12.54 Mil. Vita 34 AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was €11.94 Mil. Vita 34 AG's annualized EBITDA for the quarter that ended in Sep. 2023 was €9.06 Mil. Vita 34 AG's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 was 2.70.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Vita 34 AG's Debt-to-EBITDA or its related term are showing as below:

XTER:V3V' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.85   Med: 0.89   Max: 34.61
Current: -1.85

During the past 13 years, the highest Debt-to-EBITDA Ratio of Vita 34 AG was 34.61. The lowest was -1.85. And the median was 0.89.

XTER:V3V's Debt-to-EBITDA is ranked worse than
100% of 423 companies
in the Healthcare Providers & Services industry
Industry Median: 2.61 vs XTER:V3V: -1.85

Vita 34 AG Debt-to-EBITDA Historical Data

The historical data trend for Vita 34 AG's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vita 34 AG Debt-to-EBITDA Chart

Vita 34 AG Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.75 1.33 1.06 34.61 -1.59

Vita 34 AG Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.08 -0.41 17.05 4.77 2.70

Competitive Comparison of Vita 34 AG's Debt-to-EBITDA

For the Medical Care Facilities subindustry, Vita 34 AG's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vita 34 AG's Debt-to-EBITDA Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Vita 34 AG's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Vita 34 AG's Debt-to-EBITDA falls into.



Vita 34 AG Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Vita 34 AG's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(16.126 + 12.054) / -17.695
=-1.59

Vita 34 AG's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(12.535 + 11.939) / 9.064
=2.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2023) EBITDA data.


Vita 34 AG  (XTER:V3V) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Vita 34 AG Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Vita 34 AG's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Vita 34 AG (XTER:V3V) Business Description

Traded in Other Exchanges
Address
Deutscher Platz 5a, Leipzig, DEU, D-04103
Vita 34 AG is an umbilical cord blood bank. It supplies cryo-preservation and provides for the logistics to collect the blood, the preparation and the storage of stem cells from umbilical cord blood and tissue. The Group has two strategic areas that constitute the Group's reportable segments. Both segments are active in the field of stem cell banking, but differ in their organizational and operational structure with separate financial information. The products and services of the two segments correspond to the service portfolios of the two subgroups PBKM and Vita 34. It operates in Germany, Spain, and other international countries, of which maximum revenue is derived from the business operations in Germany.
Executives
Jakub Julian Baran Member of the Management Board
Dr. Alexander Granderath Supervisory Board

Vita 34 AG (XTER:V3V) Headlines

No Headlines